May. 5 at 8:39 PM
$NBIX
🚨🚨🚨🚨
Neurocrine Biosciences reported sharply stronger Q1 2026 results, with net income of
$197.9 million and diluted EPS of
$1.91, up from
$0.08 a year earlier.
Total revenues rose to
$814.5 million from
$572.6 million, driven by INGREZZA net product sales of
$656.9 million and CRENESSITY net product sales of
$153.3 million as demand and new prescriptions grew.
Operating income increased to
$193.4 million, helped by a
$28.6 million gain on the sale of Neurocrine Group Limited and higher investment and equity gains.
Neurocrine ended the quarter with
$2.65 billion in cash, cash equivalents and marketable securities and generated
$145.8 million of operating cash flow, while repurchasing
$56.0 million of stock.
The company agreed to acquire Soleno Therapeutics for approximately
$2.9 billion in cash and expects to fund the deal with cash and investments, which will significantly reduce its cash balances.
